New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in Clinical Ophthalmology showed that a consistent cohort of 107 open-angle glaucoma (OAG) eyes receiving the iStent® Trabecular Micro-Bypass Stent in combination with cataract surgery achieved a 22% reductio
